P-105 - Improvement of the advanced lipoprotein profile in subjects with new-onset type 2 diabetes mellitus after glucose optimization
aInstitut de Recerca de l’hospital de la Santa Creu i Sant Pau i Institut d’investigació Biomèdica Sant Pau, IIb-Sant Pau, Barcelona, Spain. bDepartament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. cBiosfer Teslab, SL, Reus, Spain. dPlataforma de Metabolómica Universitat Rovira i Virgili (URV); Instituto de Investigación Sanitaria Pere Virigili (IISPV), Tarragona, Spain. eCIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Madrid, Spain. fServei d’Endocrinologia i Nutrició, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. gDepartment de Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. hServei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. iServei d’Endocrinologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Objectives: The impact of glycemic optimization on lipoprotein subfraction parameters in dyslipidemic subjects with new-onset type 2 diabetes mellitus (T2D) was examined.
Material and methods: We evaluated the serum lipid and advanced lipoprotein profiles in twenty-one subjects at onset of T2D by laboratory methods and 1H-NMR spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal glycemic control (HbA1c ≤ 7.0%).
Results: Lipoprotein analysis revealed a significant reduction from baseline in predictive ratios of cardiovascular risk (Total cholesterol/HDL-C: -15%; LDL-C/HDL-C: -23% and VLDL-C + LDL-C/HDL-C: -18%; p < 0.05). Mainly attributed to increased HDL (9%) concentration and a concomitant increment of small-size HDL (15%). Notably, related surrogates of atherogenicity were resolved upon achievement of optimal glycemic status.
Conclusions: Our data showed that the optimization of glucose after T2D onset improved HDL levels and that are related to lower cardiovascular risk.
